Comparative pharmacoeconomic analysis of medication for patients after acute decompensated heart failure

• Published in: Rossiĭskiĭ kardiologicheskiĭ zhurnal Vol. 25; no. 1; pp. 65 - 71
• Main Authors: Zyryanov, S. K., Ushkalova, E. A.
• Format: Journal Article
• Language: English
• Published: FIRMA «SILICEA» LLC 10.02.2020
• Subjects: alsartan+sacubitril; budget impact analysis; cost-effectiveness analysis; heart failure; life years gained
• ISSN: 1560-4071; 2618-7620
• DOI: 10.15829/1560-4071-2020-1-3690

Aim. Pharmacoeconomic comparison of medication management strategies (valsartan+ sacubitril) for patients with heart failure (HF), stabilized after an episode of acute decompensated heart failure (ADHF). Material and methods. “Cost — effectiveness analysis” and “Budget impact analysis” were used. The study is conducted in terms of the interests of Russian Federation health care system and budgets of individual regions. Results. The use of valsartan+sacubitril combination will require an increase in direct medical costs for 1 year by 38,5% compared with enalapril. The cost of one life year gained when using the valsartan+sacubitril combination was 307,294 rubles. When estimating data for the target ADHF population (n=200,769), valsartan+sacubitril will require additional 4,4 billion rubles per year. At the same time, this will save almost 17 thousand lives and prevent 126 thousand ambulance calls and 33,9 thousand rehospitalizations, including more than 6,5 thousand in the intensive care unit. Conclusion. The use of valsartan+sacubitril combination in HF patients hospitalized with ADHF is cost-effective management strategy that significantly improves the prognosis in this category of patients.